enVVeno Medical (NVNO) Cash & Equivalents (2017 - 2026)

enVVeno Medical has reported Cash & Equivalents for 10 years, with the latest figure at $2.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 11.58% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $2.6 million (down 11.58% YoY), and the FY2025 full-year result was $3.1 million, up 74.74% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $2.6 million, down from $3.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $51.3 million in Q1 2022, with the low at $1.5 million in Q3 2025.
• Average Cash & Equivalents over 5 years is $8.9 million, with a median of $3.1 million recorded in 2025.
• Year-over-year, Cash & Equivalents slumped 95.0% in 2022 and jumped 262.21% in 2024.
• Tracing NVNO's Cash & Equivalents over 5 years: stood at $4.6 million in 2022, then dropped by 20.53% to $3.6 million in 2023, then sank by 51.55% to $1.8 million in 2024, then jumped by 74.74% to $3.1 million in 2025, then slipped by 15.27% to $2.6 million in 2026.
• The last three Cash & Equivalents figures came in at $2.6 million (Q1 2026), $3.1 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.

Peer Comparison